Crestline Management LP acquired a new stake in shares of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 183,687 shares of the biopharmaceutical company’s stock, valued at approximately $753,000. Crestline Management LP owned about 0.49% of OncoMed Pharmaceuticals as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. BlueCrest Capital Management Ltd bought a new position in OncoMed Pharmaceuticals during the fourth quarter valued at $133,000. Paloma Partners Management Co bought a new position in OncoMed Pharmaceuticals during the fourth quarter valued at $135,000. Virtu Financial LLC bought a new position in OncoMed Pharmaceuticals during the fourth quarter valued at $170,000. Goldman Sachs Group Inc. lifted its position in OncoMed Pharmaceuticals by 89.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 52,106 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 24,653 shares during the last quarter. Finally, Spark Investment Management LLC bought a new stake in shares of OncoMed Pharmaceuticals in the 4th quarter worth about $228,000. Institutional investors and hedge funds own 53.47% of the company’s stock.
Several equities research analysts have recently issued reports on OMED shares. Cantor Fitzgerald set a $6.00 target price on shares of OncoMed Pharmaceuticals and gave the stock a “hold” rating in a report on Thursday, January 4th. Zacks Investment Research upgraded shares of OncoMed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a report on Thursday, January 4th. Finally, HC Wainwright restated a “neutral” rating on shares of OncoMed Pharmaceuticals in a report on Friday, February 23rd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $5.31.
Shares of OncoMed Pharmaceuticals stock traded down $0.08 during trading on Friday, hitting $3.08. The stock had a trading volume of 52,989 shares, compared to its average volume of 230,597. OncoMed Pharmaceuticals, Inc. has a 12 month low of $1.74 and a 12 month high of $8.89. The firm has a market capitalization of $120.90, a PE ratio of -2.96 and a beta of 1.82.
OncoMed Pharmaceuticals (NASDAQ:OMED) last announced its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.59. The company had revenue of $20.64 million for the quarter, compared to the consensus estimate of $5.10 million. equities analysts forecast that OncoMed Pharmaceuticals, Inc. will post -0.96 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “183,687 Shares in OncoMed Pharmaceuticals, Inc. (OMED) Purchased by Crestline Management LP” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/183687-shares-in-oncomed-pharmaceuticals-inc-omed-acquired-by-crestline-management-lp.html.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals, Inc discovers and develops cancer stem cell (CSC) and immuno-oncology therapeutics. The company's product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer.
Receive News & Ratings for OncoMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.